Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17829040 | 0.96 | KDM4E (0.35) | ALDH1A1MAPTCYP1A1CYP1A2CYP1B1 | |
| SCHEMBL17828848 | 0.94 | ATM (0.33) | ALDH1A1MAPTCYP1A1CYP1A2CYP1B1 | |
| SCHEMBL17828847 | 0.94 | ATM (0.35) | ALDH1A1MAPTCYP1A1CYP1A2CYP1B1 | |
| SCHEMBL17828819 | 0.93 | ALDH1A1 (0.35) | ALDH1A1MAPTCYP1A1CYP1A2CYP1B1 | |
| SCHEMBL17828851 | 0.91 | ALDH1A1 (0.37) | ALDH1A1MAPTCYP1A1CYP1A2CYP1B1 | |
| SCHEMBL17828755 | 0.91 | CYP1A2 (0.33) | MAPTCYP1A1CYP1A2CYP1B1KDM4E | |
| SCHEMBL17828826 | 0.90 | CYP1A1 (0.38) | ALDH1A1MAPTCYP1A1CYP1A2CYP1B1 | |
| SCHEMBL17828823 | 0.90 | ATM (0.34) | ALDH1A1MAPTCYP1A1CYP1A2CYP1B1 | |
| SCHEMBL17828932 | 0.89 | ATM (0.37) | CYP1A1CYP1A2CYP1B1KDM4EATM | |
| SCHEMBL17828850 | 0.89 | CYP1A1 (0.37) | ALDH1A1MAPTCYP1A1CYP1A2CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9508939-B2 | Compound and organic electroluminescent element produced using same | IDEMITSU KOSAN CO., LTD. (JP) | 2016-11-29 | — | — | US | disclosed |
| US-9508939-B2 | Compound and organic electroluminescent element produced using same | IDEMITSU KOSAN CO., LTD. (JP) | 2016-11-29 | — | — | US | disclosed |
| US-20160172604-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT PRODUCED USING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160172604-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT PRODUCED USING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160172604-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT PRODUCED USING SAME | L1CAM, LEF1, EML4 | ALDH1A1 248/4885MAPT 2279/4885CYP1A1 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.